Clinical Trial

ACB vs no Block for Pediatric ACL Reconstruction

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this randomized controlled feasibility clinical trial is to assess the feasibility of conducting a randomized trial of adding a perioperative single-shot adductor canal block to standard of care general anesthesia compared to non-regional techniques in pediatric patients undergoing arthroscopic anterior cruciate ligament (ACL) reconstruction. The main clinical question it aims to answer is does ACB result in improved Quality of Recovery-15 questionnaire scores on postoperative day 2 , postoperative day 14, and postoperative day 42. Secondary questions this study will address are will use of a single-shot adductor canal block result in: less total opioid consumption; shorter post anesthetic care unit (PACU) length of stay; better pain scores at rest and with movement at time of postoperative phone call; and patient satisfaction score at 2 weeks (postoperative day 14). Researchers will compare the scores to patients undergoing the same surgery who will not have a single-shot ACB. All patients will receive the same pre-, peri-, and postoperative care with the exception of being randomized to block or no block. Participants will be asked to answer the Quality of Recovery-15 questionnaire and rate their pain on a scale of 0-10 on the day of surgery, at postoperative day 2 (by telephone) and at postoperative day 14 and postoperative day 42 during regular orthopedic clinic follow-up. Patients and caregivers will rate their satisfaction at postoperative day 42, using a 5-item Likert scale (ranging from completely dissatisfied to completely satisfied).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-12.
Status change: Not Yet Recruiting → Recruiting 2025-09-23
Trial Details
NCT Number NCT06875427
Lead Sponsor Isabella Jaramillo
Collaborators: McMaster University
Conditions Anterior Cruciate Ligament, Anterior Cruciate Ligament (ACL) Tear
Enrollment 38 participants
Start Date 2025-07-01
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-26